- βSemaglutide's FLOW trial data confirmed 24% reduction in major kidney disease events, now reflected in expanded FDA labeling
- βTeplizumab (Tzield) is the first FDA-approved therapy to delay Type 1 diabetes onset, backed by strong European-US trial collaboration
- βVertex VX-880 cell therapy trials show early patients achieving meaningful insulin independence, representing a potential paradigm shift
European Diabetes Research: New Therapies Coming to the US
Europe has long been a proving ground for innovative diabetes therapies, with its centralized regulatory framework through the European Medicines Agency (EMA) sometimes moving faster than the FDA on select treatments. In 2025, several therapies that first gained traction in European clinical settings are now crossing the Atlantic β either through active FDA review, ongoing US trials, or accelerated approval pathways. Here's what's real, what's promising, and what patients need to know.
Tirzepatide Expands: Beyond Weight Loss into Type 1
Eli Lilly's tirzepatide (Mounjaro/Zepbound), a dual GIP and GLP-1 receptor agonist, has been a dominant force in European and US diabetes care. But European researchers have been more aggressively exploring its use in Type 1 diabetes as an adjunct therapy. The SURMOUNT and SURPASS trial programs generated enormous European enrollment data showing cardiovascular benefit, kidney protection, and weight reduction well beyond what earlier GLP-1 drugs achieved. Building on this, European centers have been running investigator-initiated studies testing tirzepatide in Type 1 diabetes to reduce insulin requirements and improve time-in-range. US researchers are now expanding similar investigations, with ClinicalTrials.gov listing several active Phase 2 studies. These are not yet FDA-approved indications β patients should not adjust insulin without physician guidance.
Semaglutide's Cardiovascular Data Reshaping Guidelines
Novo Nordisk's semaglutide (Ozempic, Wegovy) generated landmark data from the FLOW trial, published in 2024, demonstrating a 24% reduction in major kidney disease events in Type 2 diabetes patients with chronic kidney disease. European nephrologists integrated this data rapidly, and the FDA followed with expanded labeling in 2024. The SELECT trial, heavily enrolling European sites, confirmed cardiovascular mortality reduction in non-diabetic obese patients, further blurring the line between diabetes and cardiometabolic medicine. These are real, published, peer-reviewed results β not preliminary data β and they are actively changing how US physicians prescribe these medications in 2025.
PROTECT Trial: Teplizumab's Role in Type 1 Delay
One of the most significant European-US collaborative efforts involves immune-modulating therapies for Type 1 diabetes. Provention Bio's teplizumab (Tzield), now under Sanofi, received FDA approval in 2022 based partly on the TN-10 trial data and was the first drug approved to delay Stage 3 Type 1 diabetes onset. European immunology centers contributed substantially to the PROTECT trial, which studied teplizumab in newly diagnosed Type 1 diabetes patients. Results published in 2023 in the New England Journal of Medicine showed that teplizumab preserved beta cell function at 78 weeks compared to placebo, measured by C-peptide levels. This is meaningful science β slowing beta cell destruction, not just managing symptoms. US endocrinologists are now navigating how to integrate this into clinical practice, though cost and access remain significant barriers.
Cell Therapy: Vertex and European Beta Cell Science
Vertex Pharmaceuticals' VX-880 and VX-264 programs represent perhaps the most ambitious frontier in diabetes research. VX-880 involves transplanting stem cell-derived islet cells into Type 1 diabetes patients. Early trial results presented in 2023 and 2024 showed multiple patients achieving meaningful insulin independence or dramatic insulin reduction. European stem cell research institutions, particularly in Denmark and the UK, have contributed foundational science to this field. VX-264 encapsulates these cells to potentially eliminate the need for immunosuppression β a critical advancement. These trials are ongoing, with ClinicalTrials.gov listings active for US and European sites. This is genuinely exciting but genuinely early β we are talking about a small number of patients with significant follow-up still needed before this becomes a standard therapy.
Closed-Loop Insulin Delivery: European Approval Leading US Access
Europe's regulatory speed on advanced hybrid closed-loop systems has repeatedly preceded US approval. Beta Bionics' iLet Bionic Pancreas received FDA approval in 2023 after strong European pilot data, and Medtronic's MiniMed 780G β widely used across Europe for years β gained US FDA approval in 2023. In 2025, the next generation of fully automated systems continue to advance, with European real-world data consistently showing Time-in-Range improvements exceeding 70-75% in diverse patient populations. For patients managing devices and supplies today, resources like mdsdiabetes.com provide current CGM and insulin pump supplies while these next-generation systems complete their approval pathways.
Current Status (2025)
- Tirzepatide for T1D: Investigational only; active Phase 2 trials on ClinicalTrials.gov
- Semaglutide kidney/CV expansion: FDA-approved expanded indications; actively prescribed now
- Teplizumab (Tzield): FDA-approved for delay of Stage 3 T1D; access expanding slowly
- Vertex VX-880/VX-264: Phase 1/2 trials ongoing; years from potential approval
- MiniMed 780G / iLet: FDA-approved and commercially available in the US
Timeline: When Can Patients Expect Access?
Semaglutide and tirzepatide expansions are happening now. Teplizumab is available but navigating insurance hurdles. Cell therapies like VX-880 are realistically 5-8 years from broad availability if trials continue successfully. Closed-loop device improvements will continue on 2-3 year cycles based on current regulatory trends.
What This Means for Patients
The pipeline from European research to US clinical practice is real and accelerating. Patients with Type 1 diabetes who are antibody-positive but not yet diagnosed with Stage 3 diabetes should ask their endocrinologist about teplizumab screening. Those with Type 2 diabetes and kidney disease should confirm their physician is aware of the FLOW trial data and semaglutide's updated indications. Anyone interested in cell therapy trials can search NCT numbers on ClinicalTrials.gov for Vertex programs. Most importantly, the best outcomes today still depend on optimizing current tools β CGM adherence, insulin management, and proper supplies β while these next-generation therapies mature.